دورية أكاديمية
Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
| العنوان: | Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors. |
|---|---|
| المؤلفون: | Huang XJ; Xiangya Nursing of School, Central South University, Changsha 410013, Hunan Province, China., Yin M; Xiangya Nursing of School, Central South University, Changsha 410013, Hunan Province, China., Zhou BQ; Xiangya Nursing of School, Central South University, Changsha 410013, Hunan Province, China., Tan XY; Xiangya Nursing of School, Central South University, Changsha 410013, Hunan Province, China., Xia YQ; School of Medicine, Jishou University, Jishou 416000, Hunan Province, China., Qin CX; Department of Health Examination Center, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China. chunxiangqin@csu.edu.cn. |
| المصدر: | World journal of hepatology [World J Hepatol] 2023 Aug 27; Vol. 15 (8), pp. 985-1000. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101532469 Publication Model: Print Cited Medium: Print ISSN: 1948-5182 (Print) NLM ISO Abbreviation: World J Hepatol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing, China : Baishideng |
| مستخلص: | Background: Recently, a group of hepatologists proposed to rename non-alcoholic fatty liver disease (NAFLD) as metabolic associated fatty liver disease (MAFLD) with modified diagnostic criteria. It is important to note, however, that there are some differences between the diagnostic criteria used for NAFLD and MAFLD. Since the research on MAFLD is just beginning, however, evidence on its incidence and prevalence in the general population and in specific subpopulations remains limited. Aim: To assess epidemiology of fatty liver in new definition and compare MAFLD with NAFLD. Exploring risk factors of MAFLD individuals. Methods: This was a retrospective, cross-sectional study. A total of 85242 adults were selected from the Chinese health management database in 2017-2022. The data of general information, laboratory indicators, lifestyle management and psychological status were obtained. MAFLD was diagnosed as ultrasound diagnosis of fatty liver and at least one between these three conditions: Overweight/obesity, type 2 diabetes mellitus (T2DM) or metabolic dysregulation. Metabolic factors were not considered in NAFLD diagnosis standard. The clinical characteristics of MAFLD and NAFLD were analysed using descriptive statistics. Continuous variables normally distributed were expressed as means ± SD. Categorical variables were expressed as frequencies and proportions. Binary logistic regression was used to determine risk factors of the MAFLD. Results: The prevalence of MAFLD and NAFLD was 40.5% and 31.0%, respectively. The MAFLD or NAFLD population is more likely to be older (M: 47.19 ± 10.82 vs 43.43 ± 11.96; N: 47.72 ± 11.17 vs 43.71 ± 11.66), male (M: 77.21% vs 44.43%; N: 67.90% vs 53.12%) and high body mass index (M: 26.79 ± 2.69 vs 22.44 ± 2.48; N: 26.29 ± 2.84 vs 23.29 ± 3.12) than the non-MAFLD or non-MAFLD population. In multivariate analysis, general information ( e.g. , ≥ 2 metabolic abnormalities OR = 3.38, (95%CI: 2.99-3.81), P < 0.001; diastolic blood pressure OR = 1.01, (95%CI: 1.00-1.01), P = 0.002), laboratory results [ e.g. ,total bilirubin (TBIL) OR = 0.98, (95%CI: 0.98-0.99), P < 0.001; serum uric acid(SUA) OR = 1.01, (95%CI: 1.01-1.01), P < 0.001], and lifestyle factors [ e.g. , drink beverage OR = 0.32, (95%CI: 0.17-0.63), P = 0.001] were influence factors for MAFLD. Our study results offer new insight into potential risk factors associated with fatty liver disease, including SUA, TBIL and creatinine, all of which are related to chronic renal disease (CKD). Conclusion: MAFLD is more prevalent than NAFLD, with two-fifths of individuals meeting the diagnosis criteria. MAFLD and NAFLD populations have different clinical characteristics. CKD may be related with MAFLD. Competing Interests: Conflict-of-interest statement: The authors have no conflicts to disclose. (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | Hepatology. 2020 Oct;72(4):1230-1241. (PMID: 31991487) Clin Gastroenterol Hepatol. 2022 Dec;20(12):2809-2817.e28. (PMID: 34890795) Int J Environ Res Public Health. 2020 Mar 11;17(6):. (PMID: 32168920) Clin Nutr. 2021 May;40(5):2508-2519. (PMID: 33932796) Therap Adv Gastroenterol. 2016 May;9(3):417-8. (PMID: 27134669) Clin Liver Dis (Hoboken). 2018 Apr 20;11(4):81. (PMID: 30992795) Liver Int. 2020 Sep;40(9):2082-2089. (PMID: 32478487) Clin Gastroenterol Hepatol. 2021 Oct;19(10):2138-2147.e10. (PMID: 33348045) Dig Liver Dis. 2010 Jul;42(7):503-8. (PMID: 19766548) Front Immunol. 2022 Sep 15;13:925690. (PMID: 36189280) J Clin Endocrinol Metab. 2022 Aug 18;107(9):2691-2700. (PMID: 35587339) Lancet Diabetes Endocrinol. 2020 Jul;8(7):616-627. (PMID: 32559477) J Diabetes Complications. 2016 Sep-Oct;30(7):1300-7. (PMID: 27324705) Biomedicines. 2023 Mar 13;11(3):. (PMID: 36979861) Medicine (Baltimore). 2018 Mar;97(9):e0021. (PMID: 29489647) Front Endocrinol (Lausanne). 2023 Mar 23;14:1160625. (PMID: 37033220) Liver Int. 2021 Jun;41(6):1290-1293. (PMID: 33590934) J Health Popul Nutr. 2021 May 3;40(1):21. (PMID: 33941292) Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):387-388. (PMID: 32461575) J Endocrinol Invest. 2022 Dec;45(12):2233-2245. (PMID: 35896944) Front Endocrinol (Lausanne). 2022 Jul 20;13:869579. (PMID: 35937795) Mediators Inflamm. 2021 Dec 07;2021:6642246. (PMID: 34916874) Front Endocrinol (Lausanne). 2022 Mar 14;13:857110. (PMID: 35360054) World J Gastroenterol. 2020 Apr 21;26(15):1792-1804. (PMID: 32351294) BMC Gastroenterol. 2020 Apr 6;20(1):88. (PMID: 32252638) J Hepatol. 2019 Oct;71(4):793-801. (PMID: 31279902) Expert Rev Gastroenterol Hepatol. 2021 Apr;15(4):345-352. (PMID: 33270482) J Pers Med. 2022 Nov 26;12(12):. (PMID: 36556179) Hepatol Int. 2021 Apr;15(2):366-379. (PMID: 33580453) Platelets. 2010;21(1):29-32. (PMID: 19947902) Dig Dis Sci. 2022 Oct;67(10):4919-4928. (PMID: 35579799) J Hepatol. 2017 Dec;67(6):1274-1280. (PMID: 28870674) Clin Gastroenterol Hepatol. 2021 Oct;19(10):2161-2171.e5. (PMID: 33137486) Clin Epidemiol. 2018 Jan 15;10:121-132. (PMID: 29391834) Nutr Metab Cardiovasc Dis. 2023 Jun;33(6):1179-1189. (PMID: 36964061) Clin Gastroenterol Hepatol. 2022 Mar;20(3):e573-e582. (PMID: 33618024) Diabetologia. 2016 Jun;59(6):1121-40. (PMID: 27053230) Eur J Gastroenterol Hepatol. 2022 Jun 1;34(6):686-692. (PMID: 35102112) BMJ Open. 2021 Dec 15;11(12):e056260. (PMID: 34911725) J Hepatol. 2020 Dec;73(6):1575. (PMID: 32933781) Clin Gastroenterol Hepatol. 2021 Apr;19(4):788-796.e4. (PMID: 32407969) |
| فهرسة مساهمة: | Keywords: Characteristics; Cross-section study; Epidemiology; Metabolic (dysfunction)-associated fatty liver disease; Non-alcoholic fatty liver disease; Risk factors |
| تواريخ الأحداث: | Date Created: 20230913 Latest Revision: 20230915 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10494565 |
| DOI: | 10.4254/wjh.v15.i8.985 |
| PMID: | 37701916 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1948-5182 |
|---|---|
| DOI: | 10.4254/wjh.v15.i8.985 |